Skip to content

Telomir Pharmaceuticals, Inc.: 10-Q filed 2026-08-13

What Telomir Pharmaceuticals, Inc. reported in its quarterly report filed 2026-08-13 (fiscal Q2 2026): 24 published measures, 73 facts as tagged in accession 0001493152-26-037854.

This filing

Form
10-Q (quarterly report)
Filed
2026-08-13
Fiscal period
fiscal Q2 2026
Accession
0001493152-26-037854 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Telomir Pharmaceuticals, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2026-06-305,365,904USD
At 2025-12-317,341,361USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2026-06-30332,424USD
At 2025-12-311,427,991USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2026-06-305,033,480USD
At 2026-03-314,962,226USD
At 2025-12-315,913,370USD
At 2025-06-30481,223USD
At 2025-03-31-161,105USD
At 2024-12-31643,037USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-1,721,528USD91
2026-01-01 to 2026-06-30-2,712,475USD181
2026-01-01 to 2026-03-31-990,947USD90
2025-04-01 to 2025-06-30-5,069,890USD91
2025-01-01 to 2025-06-30-7,249,718USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-2,785,842USD181
2025-01-01 to 2025-06-30-1,559,577USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2026-01-01 to 2026-06-30669,458USD181
2025-01-01 to 2025-06-301,047,769USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2026-06-30-43,722,538USD
At 2025-12-31-41,010,063USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2026-04-01 to 2026-06-3060,837,460shares91
2026-01-01 to 2026-06-3047,682,300shares181
2025-04-01 to 2025-06-3030,010,165shares91
2025-01-01 to 2025-06-3030,265,285shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2026-04-01 to 2026-06-3060,837,460shares91
2026-01-01 to 2026-06-3047,682,300shares181
2025-04-01 to 2025-06-3030,010,165shares91
2025-01-01 to 2025-06-3030,265,285shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-0.79USD/shares91
2026-01-01 to 2026-06-30-1.02USD/shares181
2025-04-01 to 2025-06-30-0.17USD/shares91
2025-01-01 to 2025-06-30-0.24USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-0.79USD/shares91
2026-01-01 to 2026-06-30-1.02USD/shares181
2025-04-01 to 2025-06-30-0.17USD/shares91
2025-01-01 to 2025-06-30-0.24USD/shares181

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2026-01-01 to 2026-06-30238,537USD181
2025-01-01 to 2025-06-306,040,136USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2026-06-305,365,904USD
At 2025-12-317,341,361USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2026-06-30332,424USD
At 2025-12-311,427,991USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2026-04-01 to 2026-06-301,764,676USD91
2026-01-01 to 2026-06-302,806,012USD181
2025-04-01 to 2025-06-305,069,910USD91
2025-01-01 to 2025-06-307,257,692USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2026-04-01 to 2026-06-30444,674USD91
2026-01-01 to 2026-06-30912,471USD181
2025-04-01 to 2025-06-3042,839USD91
2025-01-01 to 2025-06-30379,835USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2026-06-3068,774,956shares
At 2025-12-3134,380,971shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2026-06-3048,756,018USD
At 2025-12-3146,923,433USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-47,835,431USD91
2026-01-01 to 2026-06-30-48,826,378USD181
2025-04-01 to 2025-06-30-5,069,890USD91
2025-01-01 to 2025-06-30-7,249,718USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2026-04-01 to 2026-06-301,320,002USD91
2026-01-01 to 2026-06-301,893,541USD181
2025-04-01 to 2025-06-305,027,071USD91
2025-01-01 to 2025-06-306,877,857USD181

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2026-04-01 to 2026-06-303,028USD91
2026-01-01 to 2026-06-304,283USD181
2025-04-01 to 2025-06-301,342USD91
2025-01-01 to 2025-06-301,388USD181

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2026-04-01 to 2026-06-3043,148USD91
2026-01-01 to 2026-06-3093,537USD181
2025-04-01 to 2025-06-3020USD91
2025-01-01 to 2025-06-307,974USD181

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2026-01-01 to 2026-06-305,045USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2025-01-01 to 2025-06-301,047,769USD181

Inspect the source

Entity
Telomir Pharmaceuticals, Inc. / CIK 0001971532
Captured
SEC response SHA-256
2bf53a6ee4392d72c55462c84b1ae1101543d1b4cd3306c9906ab52eae14a73f

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001971532.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))